Our broad vision is to be a leading manufacturer of IVD products in Africa and beyond.

2016 to 2019: Land acquisition design and construction for the sicurobio building

2020 to 2022: Production instrument acquisition, installation, calibration, and validation.

2023 to 2024: Operations commenced with the hematology, blood grouping and chemistry sections market launch preparations.

2024: Launch of Sicherclone Antisera for blood group and crossmatch, CHEMIA 200, CHEMIA 400, Hemia 3D, Hemia 5D, Hemia 60 Hemia 70, Immunia 100 and Immunia stat was launched successively.